Monday, 18 Nov 2019

Biologic/Novel Rx

Datesort ascending Type Title Save
18 Nov 2019 ACR Video Emapalumab Treatment in Macrophage Activation Syndrome: Dr. Fabrizio De Benedetti
18 Nov 2019 ACR Video Biosimilars: Dr. Arthur Kavanaugh
18 Nov 2019 Social The FDA has approved Pfizers new adadliumab biosimilar - Abrilada (adalimumab-afzb), this is the 5th adalimumab biosimilar to be approved (none are commercially available in the USA until 2023). Abrilada is the 25th biosimilar approved in the U.S. https://t.co/Z0tp3D5yOd
13 Nov 2019 Social RT @CCalabreseDO: Continue or stop biologics for RA if pregnant? Abstr# 2292 and 2279 show increase in flares, GC use, if biologics stopped…
13 Nov 2019 Social RT @Janetbirdope: Tofa is not different from bDMARDs in Corrona for cancer and deaths. reassuring and adds to growing safety data #ACR #ACR…
13 Nov 2019 Social RT @EBRheum: Great talk by Dr. Manzi for Year in Review! See my recent podcast about SPIRIT-H2H. It shows that IXE > ADA for skin but NO…
12 Nov 2019 Social RT @DrKanikaMonga: Efficacy and Safety of Upadacitinib in a Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase 2/3 Clinical St…
12 Nov 2019 Social RT @hausmannMD: Secukinumab: a human IgG1κ monoclonal antibody that binds to IL-17A ASAS40: a composite measure including patient global,…
12 Nov 2019 Social RT @DrPetryna: Do you routinely consider ACPA status in your choice of Biologic MOA?
12 Nov 2019 Social RT @hausmannMD: Telitacicept is a recombinant fusion protein with the extracellular domain of TACI and the FC domain of human IgG1. #ACR19…
12 Nov 2019 Social RT @uptoTate: Drs. Davila and Solow say “No good data to suggest that biologic DMARDs contribute to progression of MGUS so okay to treat as…
12 Nov 2019 Social RT @uptoTate: Spending and price trending of bDMARDs. https://t.co/gB6xjvialr #ACR19 @RheumNow plenary#2731 https://t.co/YNpwYvTu1y
12 Nov 2019 Social RT @philipcrobinson: Yes, you read that right US$5,000,000,000 increase in biological DMARD spending #ACR19 @RheumNow Abs 2731 https://t.co…
12 Nov 2019 Social RT @EBRheum: @RheumNow Should note this was not the first JAKi in this space; similar trial using tofacitinib in 2017 https://t.co/NrEul0wL…
11 Nov 2019 Social RT @EBRheum: So much JAKi right now - RA, PsA, SLE, and more! Last tweet of the day. Curious to hear... Which JAKi do you think will win…
10 Nov 2019 Social RT @MaeveGamble: Abstr#548: Efficacy and safety of subcut CT-P13 (IFX biosimilar) 1 year after switching from IV CT-P13 in pts with RA. Non…
06 Nov 2019 News New EMA Warnings for Tofacitinib in Patients at Risk for Clots
23 Oct 2019 News FDA Approves Ustekinumab for Ulcerative Colitis
21 Oct 2019 News Interleukin Targeted Biologics Increase Risks of Infection
12 Oct 2019 Slide of the day Adverse Effects of Newer Agents 2019